Open sidebar
Reports

OpenSAFELY Service Restoration Observatory: Eleven key measures for monitoring general practice clinical activity during COVID-19

Description
The COVID-19 pandemic has had a significant impact on delivery of NHS care. We have developed the OpenSAFELY Service Restoration Observatory (SRO) to describe this impact on primary care activity and monitor its recovery. This report accompanies the preprint linked below and describes changes in activity throughout the pandemic for 11 key measures of primary care activity, selected in collaboration with a clinical advisory group considering the following criteria: high volume usage, clinically relevant to front-line practice and whether they are more widely indicative of other problems in service delivery across the NHS. This analysis uses federated analytics on 48 million adults' primary care records, including all adults registered at either a TPP or EMIS practice (>95% of English practices). A regularly updated monthly dashboard is linked below (TPP practices only).
Authors
Louis Fisher, Helen J. Curtis, Richard Croker, Milan Wiedemann, Victoria Speed, Christopher Wood, Andrew Brown, Lisa EM Hopcroft, Rose Higgins, Jon Massey, Peter Inglesby, Caroline E. Morton, Alex J. Walker, Jessica Morley, Amir Mehrkar, Seb Bacon, George Hickman, Orla Macdonald, Tom Lewis, Marion Wood, Martin Myers, Miriam Samuel, Robin Conibere, Wasim Baqir, Harpreet Sood, Charles Drury, Kiren Collison, Chris Bates, David Evans, Iain Dillingham, Tom Ward, Simon Davy, Rebecca M. Smith, William Hulme, Amelia Green, John Parry, Frank Hester, Sam Harper, Jonathan Cockburn, Shaun O'Hanlon, Alex Eavis, Richard Jarvis, Dima Avramov, Paul Griffiths, Aaron Fowles, Nasreen Parkes, Brian MacKenna, Ben Goldacre
Contact
Get in touch and tell us how you use this report or new features you'd like to see: team@opensafely.org
First published
10 May 2021
Last released
12 May 2023
Links

The aim of the OpenSAFELY SRO is to describe trends and variation in clinical activity codes to evaluate NHS service restoration during the COVID-19 pandemic.

This report provides a set of key measures of general practice activity, that are indicative of changes in overall activity throughout the COVID-19 pandemic. These key measures were selected from a range of clinical areas, prioritising clinical topics that would benefit from routine monitoring and targeted action considering the following criteria: high volume usage, clinically relevant to front-line practice and whether they are more widely indicative of other problems in service delivery across the NHS (for example a decrease in records for blood tests for kidney function may be a true drop in GPs requesting these tests or it may be related to delays in laboratories processing the results).

For each of these measures we provide a link to the codelist containing all the codes used for that measure, a description of what the measure is and a brief overview of why the measure is important. We also highlight any caveats, where there are any, for each measure. For each measure we also indicate the number of unique patients recorded as having at least one event indicated by the measure as well as the total number of events since January 2019.

Monthly rates of recorded activity are displayed as practice level decile charts to show both the general trend and practice level variation in activity changes. Accompanying each chart is a summary of the most commonly recorded SNOMED-CT codes for each measure. Using the rate in April 2019 as a baseline, we calculate the percentage change from baseline in April 2020 (1st national lockdown) and April 2021. These changes are used to give an overall classification of activity change as described in the box below.

  • No change: no change from baseline in both April 2020 and April 2021.
  • Increase: an increase from baseline in either April 2020 or April 2021.
  • Sustained drop: a drop from baseline of >15% in April 2020 which has not returned to within 15% of the baseline by April 2021.
  • Recovery: a drop of >15% from baseline in April 2020 which has returned to within 15% of the baseline by April 2021.

Summary of results

These key measures demonstrated substantial changes in clinical activity throughout the COVID-19 pandemic. Six of the measures recovered to their pre-pandemic baseline within a year of the pandemic, showing a rapid, adaptive response by primary care in the midst of a global health pandemic. The remaining five measures showed a more sustained drop in activity; asthma and COPD reviews did not recover to their pre-pandemic baseline until around August 2021 and blood pressure monitoring, cardiovascular disease risk assessment and medication reviews had a sustained drop in activity that persisted up to December 2021.

Findings in context

Discussion of the specific causes and reasons for the changes in narrow measures of clinical activity we have described is best addressed through quantitative analyses that identify practices in high and low deciles to approach for targeted qualitative interviews with patients and front line staff. However we believe the following broad points may help aid interpretation. Our measures reflect only a few areas of high volume clinical activity; decreases may reflect appropriate prioritisation of other clinical activity. For example NHS Health Checks, which are used to detect early signs of high blood pressure, heart disease or type 2 diabetes, were paused during the pandemic; this is likely to explain the sustained drop in activity in cardiovascular disease risk assessment and blood pressure monitoring. However, in specific cases this may reflect changes in the style of delivery of a clinical activity, rather than the volume: for example, where patients record their own blood pressure at home since, as we have previously highlighted, home monitoring of blood pressure may not be recorded completely or consistently in GP records. In addition, not all reductions should be interpreted as problematic: as part of the COVID-19 recovery, health systems are aiming to be more resilient, responsive and sustainable; complete recovery may not always be appropriate and reductions in clinical activity across some domains may reflect rational reprioritisation of activity. Where these changes in priority have not been nationally planned, data analyses such as ours may help to rapidly identify the pragmatic changes in prioritisation being made by individual dispersed organisations or people across the healthcare ecosystem before those changes are explicitly surfaced or discussed through other mechanisms. For more detail, please see our preprint here

Blood Pressure Monitoring

The codes used for this measure are available in this codelist.

What is it and why does it matter?

A commonly-used assessment used to identify patients with hypertension or to ensure optimal treatment for those with known hypertension. This helps ensure appropriate treatment, with the aim of reducing long term risks of complications from hypertension such as stroke, myocardial infarction and kidney disease.

Caveats

We use codes which represent results reported to GPs so tests requested but not yet reported are not included. Only test results returned to GPs are included, which will usually exclude tests requested while a person is in hospital and other settings like a private clinic.

Rate per 1000 registered patients

Practices included: 6366

Most Common Codes (Codelist)

Code Description Proportion of Codes (%)
72313002 Systolic arterial pressure 96.18
413606001 Average home systolic blood pressure 2.54
407554009 Sitting systolic blood pressure 0.42
400974009 Standing systolic blood pressure 0.37
314449000 Average 24 hour systolic blood pressure 0.09

Total patients: 27.77M (79.30M events)

Change in median from April 2019 (65.03) - April 2020 (9.22): -85.82%

Change in median from April 2019 (65.03) - April 2021 (37.7): -42.03%

Overall classification: sustained drop

Cardiovascular Disease 10 year Risk Assessment

The codes used for this measure are available in this codelist.

What is it and why does it matter?

A commonly-used risk assessment used to identify patients with an increased risk of cardiovascular events in the next 10 years. This helps ensure appropriate treatment, with the aim of reducing long term risks of complications such as stroke or myocardial infarction.

Rate per 1000 registered patients

Practices included: 6351

Most Common Codes (Codelist)

Code Description Proportion of Codes (%)
718087004 QRISK2 cardiovascular disease 10 year risk score 96.49
763244005 QRISK cardiovascular disease 10 year risk calculator score 2.62
1085871000000105 QRISK3 cardiovascular disease 10 year risk calculator score 0.63
752451000000100 Cardiovascular disease risk assessment by third party 0.17
450759008 Framingham coronary heart disease 10 year risk score 0.08

Total patients: 7.38M (10.49M events)

Change in median from April 2019 (6.65) - April 2020 (0.61): -90.83%

Change in median from April 2019 (6.65) - April 2021 (4.14): -37.74%

Overall classification: sustained drop

Cholesterol Testing

The codes used for this measure are available in this codelist.

What is it and why does it matter?

A commonly-used blood test used as part of a routine cardiovascular disease 10 year risk assessment and also to identify patients with lipid disorders (e.g. familial hypercholesterolaemia). This helps ensure appropriate treatment, with the aim of reducing long term risks of complications such as stroke or myocardial infarction.

Caveats

We use codes which represent results reported to GPs so tests requested but not yet reported are not included. Only test results returned to GPs are included, which will usually exclude tests requested while a person is in hospital and other settings like a private clinic.

Rate per 1000 registered patients

Practices included: 6356

Most Common Codes (Codelist)

Code Description Proportion of Codes (%)
1005671000000105 Serum cholesterol level 97.9
1017161000000104 Plasma total cholesterol level 2.0
850981000000101 Cholesterol level 0.09
853681000000104 Total cholesterol level 0.01
365794002 Finding of serum cholesterol level < 0.005

Total patients: 16.82M (32.71M events)

Change in median from April 2019 (23.99) - April 2020 (1.98): -91.75%

Change in median from April 2019 (23.99) - April 2021 (20.94): -12.71%

Overall classification: recovery

Liver Function Testing - Alanine Transferaminase (ALT)

The codes used for this measure are available in this codelist.

What is it and why does it matter?

An ALT blood test is one of a group of liver function tests (LFTs) which are used to detect problems with the function of the liver. It is often used to monitor patients on medications which may affect the liver or which rely on the liver to break them down within the body. They are also tested for patients with known or suspected liver dysfunction.

Caveats

In a small number of places, an ALT test may NOT be included within a liver function test. We use codes which represent results reported to GPs so tests requested but not yet reported are not included. Only tests results returned to GPs are included, which will usually exclude tests requested while a person is in hospital and other settings like a private clinic.

Rate per 1000 registered patients

Practices included: 6361

Most Common Codes (Codelist)

Code Description Proportion of Codes (%)
1018251000000107 Serum alanine aminotransferase level 95.96
1013211000000103 Plasma alanine aminotransferase level 3.83
250637003 Alanine aminotransferase - blood measurement 0.18
34608000 Alanine aminotransferase measurement 0.02
201321000000108 Serum alanine aminotransferase level < 0.005

Total patients: 23.36M (54.14M events)

Change in median from April 2019 (36.0) - April 2020 (7.47): -79.25%

Change in median from April 2019 (36.0) - April 2021 (34.91): -3.03%

Overall classification: recovery

Thyroid Testing

The codes used for this measure are available in this codelist.

What is it and why does it matter?

TSH is used for the diagnosis and monitoring of hypothyroidism and hyperthyroidism, including making changes to thyroid replacement therapy dosing.

Caveats

We use codes which represent results reported to GPs so tests requested but not yet reported are not included. Only test results returned to GPs are included, which will usually exclude tests requested while a person is in hospital and other settings like a private clinic.

Rate per 1000 registered patients

Practices included: 6361

Most Common Codes (Codelist)

Code Description Proportion of Codes (%)
1022791000000101 Serum thyroid stimulating hormone level 97.31
1022801000000102 Plasma thyroid stimulating hormone level 2.54
1027151000000105 Thyroid stimulating hormone level 0.15
61167004 Thyroid stimulating hormone measurement < 0.005
313440008 Measurement of serum thyroid stimulating hormone < 0.005

Total patients: 19.36M (36.16M events)

Change in median from April 2019 (23.65) - April 2020 (3.62): -84.69%

Change in median from April 2019 (23.65) - April 2021 (23.26): -1.65%

Overall classification: recovery

Full Blood Count - Red Blood Cell (RBC) Testing

The codes used for this measure are available in this codelist.

What is it and why does it matter?

RBC is completed as part of a group of tests referred to as a full blood count (FBC), used to detect a variety of disorders of the blood, such as anaemia and infection.

Caveats

Here, we use codes which represent results reported to GPs, so tests requested but not yet reported are not included. This will usually exclude tests requested while a person is in hospital and other settings, like a private clinic.

Rate per 1000 registered patients

Practices included: 6359

Most Common Codes (Codelist)

Code Description Proportion of Codes (%)
1022451000000103 Red blood cell count > 99.995
365625004 Finding of red blood cell count < 0.005
14089001 Red blood cell count < 0.005

Total patients: 23.82M (56.95M events)

Change in median from April 2019 (37.88) - April 2020 (8.84): -76.66%

Change in median from April 2019 (37.88) - April 2021 (37.13): -1.98%

Overall classification: recovery

Glycated Haemoglobin A1c Level (HbA1c)

The codes used for this measure are available in this codelist.

What is it and why does it matter?

HbA1c is a long term indicator of diabetes control. NICE guidelines recommend that individuals with diabetes have their HbA1c measured at least twice a year. Poor diabetic control can place individuals living with diabetes at an increased risk of the complications of diabetes.

Caveats

Here, we use codes which represent results reported to GPs, so tests requested but not yet reported are not included. This will usually exclude tests requested while a person is in hospital and other settings, like a private clinic.

Rate per 1000 registered patients

Practices included: 6362

Most Common Codes (Codelist)

Code Description Proportion of Codes (%)
999791000000106 Haemoglobin A1c level - International Federation of Clinical Chemistry and Laboratory Medicine standardised 96.47
1003671000000109 Haemoglobin A1c level 3.47
43396009 Hemoglobin A1c measurement 0.04
365845005 Hemoglobin A1C - diabetic control finding 0.02
313835008 Hemoglobin A1c measurement aligned to the Diabetes Control and Complications Trial < 0.005

Total patients: 20.57M (42.80M events)

Change in median from April 2019 (28.86) - April 2020 (3.33): -88.46%

Change in median from April 2019 (28.86) - April 2021 (28.2): -2.29%

Overall classification: recovery

Renal Function Assessment - Sodium Testing

The codes used for this measure are available in this codelist.

What is it and why does it matter?

Sodium is completed as part of a group of tests referred to as a renal profile, used to detect a variety of disorders of the kidneys. A renal profile is also often used to monitor patients on medications which may affect the kidneys or which rely on the kidneys to remove them from the body.

Caveats

Here, we use codes which represent results reported to GPs, so tests requested but not yet reported are not included. This will usually exclude tests requested while a person is in hospital and other settings, like a private clinic.

Rate per 1000 registered patients

Practices included: 6362

Most Common Codes (Codelist)

Code Description Proportion of Codes (%)
1000661000000107 Serum sodium level 97.22
1017381000000106 Plasma sodium level 2.78

Total patients: 25.07M (65.99M events)

Change in median from April 2019 (43.88) - April 2020 (9.45): -78.46%

Change in median from April 2019 (43.88) - April 2021 (41.74): -4.88%

Overall classification: recovery

Asthma Reviews

The codes used for this measure are available in this codelist.

What is it and why does it matter?

The British Thoracic Society and Scottish Intercollegiate Guidelines Network on the management of asthma recommend that people with asthma receive a review of their condition at least annually. If a patient has not been reviewed, it is possible that their asthma control may have worsened, leading to a greater chance of symptoms and admission to hospital.

Rate per 1000 registered patients

Practices included: 6348

Most Common Codes (Codelist)

Code Description Proportion of Codes (%)
394700004 Asthma annual review 62.10
394720003 Asthma medication review 12.54
401182001 Asthma monitoring by nurse 8.87
270442000 Asthma monitoring check done 5.89
401183006 Asthma monitoring by doctor 2.73

Total patients: 3.41M (7.15M events)

Change in median from April 2019 (3.61) - April 2020 (2.17): -39.89%

Change in median from April 2019 (3.61) - April 2021 (2.76): -23.55%

Overall classification: sustained drop

Chronic Obstructive Pulmonary Disease (COPD) Reviews

The codes used for this measure are available in this codelist.

What is it and why does it matter?

It is recommended by NICE that all individuals living with COPD have an annual review with the exception of individuals living with very severe (stage 4) COPD being reviewed at least twice a year. If a patient has not been reviewed, it is possible that their COPD control may have worsened, leading to a greater chance of symptoms and admission to hospital.

Rate per 1000 registered patients

Practices included: 6336

Most Common Codes (Codelist)

Code Description Proportion of Codes (%)
394703002 Chronic obstructive pulmonary disease annual review 96.49
760621000000103 Chronic obstructive pulmonary disease 6 monthly review 2.08
760601000000107 Chronic obstructive pulmonary disease 3 monthly review 1.43

Total patients: 1.16M (2.60M events)

Change in median from April 2019 (1.1) - April 2020 (0.3): -72.73%

Change in median from April 2019 (1.1) - April 2021 (0.77): -30.0%

Overall classification: sustained drop

Medication Reviews

The codes used for this measure are a combination of codes available in this NHS Digital care planning medication review refset and this primary care domain medication review refset.

What is it and why does it matter?

Many medicines are used long-term and they should be reviewed regularly to ensure they are still safe, effective and appropriate. Medication review is a broad term ranging from a notes-led review without a patient, to an in-depth Structured Medication Review with multiple appointments and follow-up. The codelist provided captures all types of reviews to give an overview of medication reviews in primary care.

Rate per 1000 registered patients

Practices included: 6362

Most Common Codes (Codelist 1), (Codelist 2)

Code Description Proportion of Codes (%)
314530002 Medication review done 34.70
182836005 Review of medication 25.41
88551000000109 Medication review with patient 12.29
93311000000106 Medication review of medical notes 7.05
394720003 Asthma medication review 2.26

Change in median from April 2019 (34.1) - April 2020 (21.68): -36.42%

Change in median from April 2019 (34.1) - April 2021 (27.8): -18.48%

Overall classification: sustained drop